

Myocardial reperfusion in STEMI and the role of the antithrombotic/antiplatelet therapy

Citation for published version (APA):

Fabris, E. (2019). *Myocardial reperfusion in STEMI and the role of the antithrombotic/antiplatelet therapy*. [Doctoral Thesis, Maastricht University]. Maastricht University. <https://doi.org/10.26481/dis.20190628ef>

Document status and date:

Published: 01/01/2019

DOI:

[10.26481/dis.20190628ef](https://doi.org/10.26481/dis.20190628ef)

Document Version:

Publisher's PDF, also known as Version of record

Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

www.umlib.nl/taverne-license

Take down policy

If you believe that this document breaches copyright please contact us at:

repository@maastrichtuniversity.nl

providing details and we will investigate your claim.

STELLINGEN

Behorend bij het proefschrift

Myocardial reperfusion in STEMI and the role of the antithrombotic/antiplatelet therapy

1. The electrocardiographic assessment of myocardial reperfusion remains a prognostic marker of clinical outcomes even in the modern era of STEMI treatment - *This thesis*
2. Pre-hospital ticagrelor administration may be beneficial in STEMI patients being transported to hospitals for primary PCI, particularly when longer transfer delays can be expected - *This thesis*
3. In patients with STEMI, the “patient delay” must be minimized as much as possible for improving myocardial reperfusion - *This thesis*
4. Diabetes mellitus remains an independent predictor of poor myocardial reperfusion even in STEMI patients treated with early antithrombotic treatment and despite fast cath-lab transfer time - *This thesis*
5. Heparin remains the anticoagulant of choice in patient with STEMI undergoing primary PCI - *This thesis*
6. An high-risk subset of STEMI patients, as identified by higher levels of NT-proBNP upon presentation, may derive particular benefit from early GPIs treatment - *This thesis*
7. Limiting DAPT duration to six months in event-free STEMI patients is safe, and may be considered in patients with high bleeding risk or if clinically mandated - *This thesis*
8. Medicine is a science of uncertainty and an art of probability - *William Osler*
9. The scientist is not a person who gives the right answers, he is one who asks the right questions - *Claude Levi-Strauss*
10. Pro veritate adversa diligere (for love of truth, I willingly go to confront difficulties) - *Carlo Maria Martini*